Opus Genetics (IRD) EPS (Weighted Average and Diluted) (2016 - 2026)
Opus Genetics (IRD) reported EPS (Weighted Average and Diluted) of -$0.75 for Q1 2026, down 212.5% year-over-year from $0.67 in Q1 2025, and down 257.14% on a QoQ basis from -$0.21 in Q4 2025.
Opus Genetics (IRD) has 10 years of EPS (Weighted Average and Diluted) data on file, last reported at -$0.75 in Q1 2026.
- Quarterly EPS (Weighted Average and Diluted) fell 212.5% year-over-year to -$0.75 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$1.33 (up 36.67% YoY) and the FY2025 annual result came in at -$0.8, up 62.79% from the prior year.
- EPS (Weighted Average and Diluted) eased to -$0.75 in Q1 2026 per IRD's latest filing, from -$0.21 in the prior quarter.
- Across five years, EPS (Weighted Average and Diluted) topped out at $1.69 in Q4 2022 and bottomed at -$1.27 in Q4 2024.
- The 5-year median for EPS (Weighted Average and Diluted) is -$0.25 (2022), against an average of -$0.2.
- The widest annual swing landed in 2022, when EPS (Weighted Average and Diluted) surged 1038.89%; it then tumbled 504.76% in 2024.
- Tracing IRD's EPS (Weighted Average and Diluted) over 5 years: stood at $1.69 in 2022, then plunged by 112.43% to -$0.21 in 2023, then plunged by 504.76% to -$1.27 in 2024, then surged by 83.46% to -$0.21 in 2025, then slumped by 257.14% to -$0.75 in 2026.
- Per Business Quant, the three latest IRD EPS (Weighted Average and Diluted) figures stand at -$0.75 (Q1 2026), -$0.21 (Q4 2025), and -$0.25 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -4.43 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 3,086.42 |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 0.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 4.02 |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 6.75 |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 1.51 |
| 10 | Opus Genetics | 357.99 Mn | 298.03 Mn | - | -0.75 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -0.75 |
| Dec 31, 2025 | -0.21 |
| Sep 30, 2025 | -0.25 |
| Jun 30, 2025 | -0.12 |
| Mar 31, 2025 | -0.24 |
| Dec 31, 2024 | -1.27 |
| Sep 30, 2024 | -0.29 |
| Jun 30, 2024 | -0.30 |
| Mar 31, 2024 | -0.29 |
| Dec 31, 2023 | -0.21 |
| Sep 30, 2023 | 0.25 |
| Jun 30, 2023 | -0.24 |
| Mar 31, 2023 | -0.28 |
| Dec 31, 2022 | 1.69 |
| Sep 30, 2022 | -0.22 |
| Jun 30, 2022 | -0.25 |
| Mar 31, 2022 | -0.35 |
| Dec 31, 2021 | -0.18 |
| Sep 30, 2021 | -0.25 |
| Jun 30, 2021 | -0.52 |
| Mar 31, 2021 | -3.57 |
| Dec 31, 2020 | -3.67 |
| Sep 30, 2020 | -0.33 |
| Jun 30, 2020 | -0.43 |
| Mar 31, 2020 | -0.87 |
| Jun 30, 2018 | -0.12 |
| Dec 31, 2017 | -0.12 |
| Sep 30, 2017 | -0.04 |
| Jun 30, 2017 | 0.03 |
| Mar 31, 2017 | -0.91 |
| Jun 30, 2016 | -0.08 |